Your browser is no longer supported. Please, upgrade your browser.
Settings
DXCM DexCom, Inc. daily Stock Chart
DXCM [NASD]
DexCom, Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own1.90% Shs Outstand85.96M Perf Week-3.73%
Market Cap6.44B Forward P/E4408.24 EPS next Y0.02 Insider Trans-15.03% Shs Float84.93M Perf Month9.16%
Income-88.10M PEG- EPS next Q-0.21 Inst Own95.40% Short Float11.31% Perf Quarter-10.80%
Sales599.40M P/S10.75 EPS this Y-8.70% Inst Trans-0.88% Short Ratio8.85 Perf Half Y19.88%
Book/sh3.26 P/B22.99 EPS next Y102.90% ROA-22.50% Target Price90.09 Perf Year-3.25%
Cash/sh2.11 P/C35.57 EPS next 5Y35.00% ROE-32.90% 52W Range57.68 - 96.38 Perf YTD25.53%
Dividend- P/FCF- EPS past 5Y-2.80% ROI-22.80% 52W High-21.85% Beta0.51
Dividend %- Quick Ratio1.70 Sales past 5Y49.70% Gross Margin66.30% 52W Low30.58% ATR2.15
Employees1900 Current Ratio1.90 Sales Q/Q22.50% Oper. Margin-14.20% RSI (14)51.61 Volatility2.72% 3.22%
OptionableYes Debt/Eq0.29 EPS Q/Q-109.30% Profit Margin-14.70% Rel Volume0.42 Prev Close74.94
ShortableYes LT Debt/Eq0.02 EarningsAug 01 AMC Payout- Avg Volume1.08M Price75.32
Recom1.70 SMA202.86% SMA503.35% SMA200-0.36% Volume383,839 Change0.51%
May-22-17Resumed Piper Jaffray Overweight
May-03-17Reiterated Canaccord Genuity Buy $95 → $90
Jan-03-17Downgrade Morgan Stanley Overweight → Equal-Weight $66
Dec-19-16Upgrade Oppenheimer Perform → Outperform
Nov-02-16Reiterated Canaccord Genuity Buy $100 → $70
Aug-03-16Reiterated The Benchmark Company Buy $86 → $106
Feb-24-16Reiterated The Benchmark Company Buy $105 → $86
Feb-08-16Downgrade Robert W. Baird Outperform → Neutral $100 → $74
Nov-02-15Initiated Morgan Stanley Overweight
Oct-15-15Upgrade Sterne Agee CRT Neutral → Buy
Oct-15-15Upgrade Leerink Partners Mkt Perform → Outperform
Sep-17-15Reiterated JP Morgan Overweight $95 → $120
Aug-06-15Reiterated Canaccord Genuity Buy $69 → $95
Jul-08-15Initiated Robert W. Baird Outperform $95
Apr-30-15Reiterated Oppenheimer Perform $64 → $69
Apr-20-15Reiterated Wedbush Outperform $73 → $80
Jan-27-15Reiterated Oppenheimer Perform $47 → $64
Aug-07-14Reiterated Canaccord Genuity Buy $40 → $48
Jun-17-14Reiterated Canaccord Genuity Buy $38 → $40
Jan-24-14Resumed Canaccord Genuity Buy $34 → $44
Jun-20-17 08:30AM  DexCom Schedules Second Quarter 2017 Earnings Release and Conference Call for August 1, 2017 at 4:30 p.m. Eastern Time Business Wire
Jun-09-17 01:27PM  3 Growth Stocks for Ambitious Investors Motley Fool
08:00AM  New Study Shows Adults with Type 1 and Type 2 Diabetes on Multiple Daily Injections (MDI) Benefit from CGM Business Wire
Jun-08-17 08:00AM  Dexcom to Add Ambulatory Glucose Profile (AGP) to Dexcom CLARITY® Business Wire
Jun-07-17 08:58AM  DexCom Shares Rise After FDA Approves G5 Mobile App for Android Devices TheStreet.com
08:05AM  DexCom wins FDA approval for G5 mobile app for android devices MarketWatch
08:00AM  DexCom Announces FDA Approval of G5 Mobile App for Android Devices Business Wire
Jun-06-17 10:04AM  Company News for June 06, 2017 Zacks
08:30AM  Strength Seen in DexCom (DXCM): Stock Adds 5% in Session Zacks
Jun-05-17 02:54PM  DexCom (DXCM) Stock Rallies on Apple Watch Partnership Zacks +5.19%
02:30PM  DexCom Stock Surging on Apple Watch Partnership TheStreet.com
02:08PM  The Apple Watch is about to get a lot more useful with swappable bands to track health symptoms CNBC
01:53PM  Apple Watch to allow glucose data pulling from Dexcom CNBC Videos
01:46PM  DexCom shares jump nearly 4% on Tim Cook's comments on glucose monitors at Apple event MarketWatch
Jun-02-17 07:20AM  DexCom (DXCM) Down 9.6% Since Earnings Report: Can It Rebound? Zacks
May-30-17 08:15AM  Post Earnings Coverage as Charles River Laboratories' Revenue Surged 25.6%, non-GAAP EPS Jumped 32% Accesswire
May-29-17 12:45PM  ETFs with exposure to DexCom, Inc. : May 29, 2017 Capital Cube
May-18-17 01:40PM  ETFs with exposure to DexCom, Inc. : May 18, 2017 Capital Cube
May-17-17 07:17PM  Cramer Remix: Here are the winners after Wednesdays mark... CNBC Videos
May-16-17 09:03AM  Will Wearable Technology Make Us Healthier? Motley Fool
05:18AM  Edited Transcript of DXCM earnings conference call or presentation 2-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-15-17 07:35PM  Some Silicon Valley techies obsessively track their blood sugar -- and they don't have diabetes CNBC
11:42AM  What's Alphabet Got to Do With Healthcare? Motley Fool
08:00AM  DexCom Announces Upcoming Conference Presentation Business Wire
May-08-17 07:57PM  DexCom Prices Offering of $350 Million of 0.75% Convertible Senior Notes Business Wire
07:09AM  DexCom Announces Proposed Offering of $300 Million of Convertible Senior Notes Business Wire
May-05-17 04:05PM  ETFs with exposure to DexCom, Inc. : May 5, 2017 Capital Cube
08:50AM  Edited Transcript of DXCM earnings conference call or presentation 2-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-04-17 10:10AM  DexCom, Inc. :DXCM-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 Capital Cube
04:00AM  Dexcom G5® Mobile Continuous Glucose Monitoring (CGM) System now Compatible with Apple Watches in Europe PR Newswire
May-03-17 04:41PM  DexCom, Inc. Value Analysis (NASDAQ:DXCM) : May 3, 2017 Capital Cube -9.48%
12:40PM  Here's Why DexCom Stock Is Tanking Today Motley Fool
08:41AM  DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss Zacks
May-02-17 05:12PM  DexCom reports 1Q loss Associated Press
04:01PM  DexCom, Inc. Reports First Quarter 2017 Financial Results Business Wire
08:10AM  DexCom, Inc. breached its 50 day moving average in a Bullish Manner : DXCM-US : May 2, 2017 Capital Cube
May-01-17 10:17AM  Medical Product Q1 Earnings Due on May 2: BDX, DXCM & More Zacks
Apr-24-17 12:47PM  Sohn Investment Conference: Investing for good CNBC Videos
Apr-19-17 08:00AM  Dexcom Has a Big Ally if Apple Gets Into Its Corner of the Diabetes Market Bloomberg
Apr-14-17 02:30PM  Dexcom adding 500 jobs in Mesa American City Business Journals
Apr-13-17 03:21PM  Is Medtronic's Artificial Pancreas the Next Big Thing in Diabetes? Motley Fool
02:53PM  Health care company Dexcom sees shares slip amid potential competition from Apple CNBC
Apr-10-17 08:32AM  DexCom, Inc. breached its 50 day moving average in a Bearish Manner : DXCM-US : April 10, 2017 Capital Cube
Apr-04-17 08:48AM  3 Hot Stocks to Buy in April Motley Fool
08:48AM  3 Hot Stocks to Buy in April
Mar-31-17 03:50AM  DexCom (DXCM) Up 4.6% Since Earnings Report: Can It Continue? Zacks
03:50AM  DexCom (DXCM) Up 4.6% Since Earnings Report: Can It Continue?
Mar-27-17 08:53AM  DexCom Gains as CMS Announces Criteria for G5 Mobile CGM Zacks
08:53AM  DexCom Gains as CMS Announces Criteria for G5 Mobile CGM
Mar-24-17 08:30AM  Medicare Announces Criteria Covering Dexcom G5 Mobile CGM for All People with Diabetes on Intensive Insulin Therapy Business Wire +8.60%
Mar-23-17 08:30AM  DexCom Schedules First Quarter 2017 Earnings Release and Conference Call for May 2, 2017 at 4:30 p.m. Eastern Time Business Wire
Mar-20-17 08:14AM  DexCom, Inc. breached its 50 day moving average in a Bullish Manner : DXCM-US : March 20, 2017 Capital Cube
08:14AM  DexCom, Inc. breached its 50 day moving average in a Bullish Manner : DXCM-US : March 20, 2017
Mar-17-17 08:06AM  3 Top Diabetes Care Stocks to Buy in 2017 Motley Fool
08:06AM  3 Top Diabetes Care Stocks to Buy in 2017 at Motley Fool
Mar-16-17 08:15AM  Post Earnings Coverage as DexCom's Q4 Top-line Surged 31%; Outshined Forecasts Accesswire
06:11AM  When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17) TheStreet.com
06:11AM  When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17)
Mar-13-17 09:02AM  DEXCOM INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
09:00AM  DexCom Appoints Richard Collins to Board of Directors Business Wire
Mar-09-17 10:06AM  Better Buy: MannKind Corp. vs. Dexcom at Motley Fool
Mar-06-17 09:02AM  DEXCOM INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet
Mar-04-17 01:04PM  DEXCOM INC Financials
Mar-03-17 09:27AM  DexCom (DXCM) Incurs Narrower Loss in Q4, Beats on Revenues
Mar-02-17 09:50AM  Billionaire George Soros Bought These 2 Biotech Stocks at Motley Fool
09:28AM  DexCom, Inc. :DXCM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017
Feb-28-17 06:55PM  DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
06:31PM  DEXCOM INC Files SEC form 10-K, Annual Report
04:01PM  DexCom, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results Business Wire
07:07AM  Q4 2016 DexCom Inc Earnings Release - After Market Close
Feb-27-17 08:54AM  Should You Buy DexCom (DXCM) Ahead of Earnings?
Feb-24-17 08:08AM  DexCom (DXCM) Q4 Earnings: What to Expect from the Stock?
Feb-22-17 04:01PM  DexCom Announces Upcoming Conference Presentations Business Wire
Feb-21-17 09:02AM  DEXCOM INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-16-17 04:09PM  DexCom Diamond 2 Results Positive, Or At Least Not As Bad As Expected
Feb-15-17 09:14PM  DexCom Is a Great Healthcare Stock to Buy Now
Feb-06-17 08:31AM  3 of the Highest-Growth Stocks in the Market Today at Motley Fool
Feb-05-17 08:00AM  5 Trade Ideas for Monday: American Express, DexCom, F5, McDonald's, Rockwell Automation
Jan-26-17 07:14PM  Alphabet's Verily Sells Stake to Temasek in Bid for Overseas Expansion at TheStreet
Jan-24-17 01:51PM  Dexcom announces publication of key study in the Journal of the American Medical Association (JAMA) demonstrating the value of CGM in reducing A1C and hypoglycemia in diabetes patients on injection therapy PR Newswire
Jan-23-17 08:30AM  DexCom Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017 at 4:30 p.m. Eastern Time Business Wire
Jan-20-17 06:00PM  Cramers Exec Cut: This stock could be a triple threat un...
10:12AM  Alcobra Leads Biotech Movers Early Friday
06:23AM  The Pain Before the Gains: Cramer's 'Mad Money' Recap (Thursday 1/19/17)
Jan-19-17 06:53PM  Cramer Remix: Stop worrying! The Trump inauguration sell-off is not here to stay at CNBC
Jan-17-17 12:52PM  Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns
12:35PM  Bullish and Bearish Reversals in the Market
Jan-13-17 07:39PM  Here's Why Insulet Corporation Rose by Double-Digits Today at Motley Fool +25.91%
07:16PM  Cramer Remix: Why banks could have juicy dividends under Trump at CNBC
06:58PM  Cramer uncovers why Wall Street didnt see DexComs monster 25% move coming at CNBC
05:26PM  Why Sanchez Energy, DexCom, and Pandora Media Jumped Today at Motley Fool
04:53PM  DexCom shares soar after diabetes product gets Medicare approval at CNBC
04:12PM  DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage
03:27PM  Why DexCom, Inc. Stock Surged Higher Today at Motley Fool
11:50AM  4 Companies That Beat Friday the 13th
Jan-12-17 09:30PM  Centers for Medicare & Medicaid Services (CMS) Classify Therapeutic Continuous Glucose Monitors (CGM) as "Durable Medical Equipment" under Medicare Part B Business Wire
09:42AM  DexCom, Inc. Value Analysis (NASDAQ:DXCM) : January 12, 2017
09:08AM  Johnson & Johnsons Diabetes Launch to Accelerate the Medical Device Business
Jan-11-17 11:56AM  DexCom: Look, but Don't Touch
09:04AM  DexCom Looking Forward to Strong Revenues in Q4 and 2016
DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patient's mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud-based reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management. The company also offers sensor augmented insulin pumps. It has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. The company was founded in 1999 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerJun 23Sale78.223,187249,27325,420Jun 27 06:56 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Jun 23Sale78.191,450113,378113,524Jun 27 06:55 PM
Balo Andrew KEVP, Clinical and RegulatoryJun 12Sale69.063,200220,989106,433Jun 13 05:27 PM
SAYER KEVIN RPresident & CEOJun 12Sale69.076,000414,411332,680Jun 13 05:26 PM
GREGG TERRANCE HExecutive ChairmanMay 24Option Exercise6.8530,000205,500484,559May 26 04:24 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerMay 23Sale68.293,182217,29028,607May 25 07:15 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.May 23Sale68.241,45098,949114,974May 25 07:16 PM
SAYER KEVIN RPresident & CEOMay 17Option Exercise8.793,64932,075347,329May 18 05:46 PM
SAYER KEVIN RPresident & CEOMay 17Sale68.398,649591,525338,680May 18 05:46 PM
Balo Andrew KEVP, Clinical and RegulatoryMay 10Sale71.933,200230,176109,633May 12 06:19 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerApr 24Sale75.783,182241,1316,369Apr 26 07:04 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Apr 24Sale75.891,450110,041117,424Apr 26 07:04 PM
GREGG TERRANCE HExecutive ChairmanApr 20Sale74.1015,0001,111,50040,882Apr 24 06:13 PM
SAYER KEVIN RPresident & CEOApr 17Option Exercise8.7910,00087,900353,680Apr 19 05:20 PM
SAYER KEVIN RPresident & CEOApr 17Sale75.6310,000756,317343,680Apr 19 05:20 PM
Balo Andrew KEVP, Clinical and RegulatoryApr 10Sale78.193,200250,208112,833Apr 12 05:31 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerMar 23Sale76.383,182243,0299,551Mar 24 05:53 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Mar 23Sale76.253,987304,006118,874Mar 24 05:54 PM
ROPER JESSSVP, CFOMar 22Sale75.972,000151,9378,452Mar 24 05:53 PM
SAYER KEVIN RPresident & CEOMar 17Option Exercise8.7910,00087,900353,680Mar 21 06:03 PM
SAYER KEVIN RPresident & CEOMar 17Sale77.8210,000778,158343,680Mar 21 06:03 PM
Leach Jacob StevenSVP, Research & DevelopmentMar 14Sale77.323,050235,82482,155Mar 15 08:40 PM
KAHN BARBARADirectorMar 14Sale77.363,000232,08021,304Mar 16 06:04 PM
VALDES JORGE ACTOMar 13Sale77.7414,4001,119,51410,442Mar 14 07:59 PM
Leach Jacob StevenSVP, Research & DevelopmentMar 13Sale77.977,926617,99185,205Mar 15 08:40 PM
Leach Jacob StevenSVP, Research & DevelopmentMar 10Option Exercise7.637,50057,22593,131Mar 15 08:40 PM
Balo Andrew KEVP, Clinical and RegulatoryMar 10Sale77.713,200248,672129,463Mar 14 07:57 PM
LISTER JOHNGeneral Manager, EMEAMar 09Option Exercise8.853,00026,55096,732Mar 10 08:49 PM
Leach Jacob StevenSVP, Research & DevelopmentMar 09Sale77.4710,341801,07295,592Mar 15 08:40 PM
LISTER JOHNGeneral Manager, EMEAMar 09Sale77.673,000233,00293,732Mar 10 08:49 PM
SKYLER JAY SDirectorMar 06Option Exercise7.3131,890233,11649,136Mar 08 06:28 PM
SKYLER JAY SDirectorMar 06Sale78.1331,8902,491,57217,246Mar 08 06:28 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerFeb 23Sale78.423,182249,53012,733Feb 24 07:52 PM
ROPER JESSSVP, CFOFeb 22Sale78.762,333183,75910,452Feb 24 07:51 PM
SAYER KEVIN RPresident & CEOFeb 17Option Exercise8.7910,00087,900309,391Feb 22 06:14 PM
SAYER KEVIN RPresident & CEOFeb 17Sale81.6210,000816,177299,391Feb 22 06:14 PM
Balo Andrew KEVP, Clinical and RegulatoryFeb 10Option Exercise9.807277,125107,072Feb 14 07:49 PM
Balo Andrew KEVP, Clinical and RegulatoryFeb 10Sale79.303,200253,760103,872Feb 14 07:49 PM
LISTER JOHNGeneral Manager, EMEAFeb 09Option Exercise8.853,00026,55073,598Feb 13 07:19 PM
VALDES JORGE ACTOFeb 09Option Exercise9.807,00068,60079,334Feb 13 07:18 PM
LISTER JOHNGeneral Manager, EMEAFeb 09Sale79.733,000239,20470,598Feb 13 07:19 PM
VALDES JORGE ACTOFeb 09Sale79.767,000558,31672,334Feb 13 07:18 PM
VALDES JORGE ACTOFeb 01Option Exercise9.8013,900136,22086,234Feb 03 07:49 PM
VALDES JORGE ACTOFeb 01Sale80.0013,9001,112,00072,334Feb 03 07:49 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Jan 23Option Exercise7.799,63775,072120,046Jan 25 08:49 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerJan 23Sale79.503,182252,97815,915Jan 25 08:49 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Jan 23Sale79.999,637770,908110,409Jan 25 08:49 PM
ROPER JESSSVP, CFOJan 18Sale85.013,012256,05112,785Jan 20 06:37 PM
SAYER KEVIN RPresident & CEOJan 17Option Exercise8.7910,00087,900309,391Jan 19 08:33 PM
SAYER KEVIN RPresident & CEOJan 17Sale85.9410,000859,362299,391Jan 19 08:33 PM
VALDES JORGE ACTOJan 13Option Exercise8.9726,100234,08082,334Jan 18 07:37 PM
LISTER JOHNGeneral Manager, EMEAJan 13Option Exercise8.8515,000132,75085,598Jan 18 07:38 PM
LISTER JOHNGeneral Manager, EMEAJan 13Sale79.3615,0001,190,40070,598Jan 18 07:38 PM
VALDES JORGE ACTOJan 13Sale80.0026,1002,088,00072,334Jan 18 07:37 PM
Balo Andrew KEVP, Clinical and RegulatoryJan 10Option Exercise9.803,20031,360109,545Jan 12 07:21 PM
Balo Andrew KEVP, Clinical and RegulatoryJan 10Sale62.863,200201,152106,345Jan 12 07:21 PM
VALDES JORGE ACTOJan 09Option Exercise7.3710,90080,29179,334Jan 11 07:31 PM
LISTER JOHNGeneral Manager, EMEAJan 09Option Exercise8.853,00026,55073,598Jan 11 07:33 PM
LISTER JOHNGeneral Manager, EMEAJan 09Sale63.023,000189,04670,598Jan 11 07:33 PM
VALDES JORGE ACTOJan 09Sale63.0210,900686,90572,334Jan 11 07:31 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerDec 23Sale62.173,182197,83119,097Dec 28 08:12 PM
ROPER JESSSVP, CFODec 14Sale64.142,442156,61915,797Dec 16 07:20 PM
VALDES JORGE ACTODec 09Option Exercise7.6010,00076,04376,259Dec 13 04:21 PM
VALDES JORGE ACTODec 09Sale64.8110,000648,07972,334Dec 13 04:21 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerNov 23Sale70.193,182223,35022,279Nov 28 07:29 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Nov 23Sale70.3210,300724,260110,409Nov 28 07:27 PM
LISTER JOHNGeneral Manager, EMEANov 09Sale62.503,417213,56370,598Nov 14 06:31 PM
ROPER JESSSVP, CFOOct 24Sale80.752,471199,54474,215Oct 26 05:08 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Oct 24Sale81.9510,300844,065120,709Oct 26 05:08 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerOct 24Sale81.123,182258,11025,461Oct 26 05:07 PM
Balo Andrew KEVP, Clinical and RegulatoryOct 19Sale82.314,997411,303106,345Oct 20 07:55 PM
SAYER KEVIN RPresident & CEOOct 14Sale81.877,000573,101299,891Oct 17 08:25 PM
VALDES JORGE ACTOOct 10Option Exercise7.6311,00083,93083,334Oct 12 08:57 PM
LISTER JOHNGeneral Manager, EMEAOct 10Sale84.413,560300,50874,015Oct 12 08:59 PM
VALDES JORGE ACTOOct 10Sale84.4211,000928,57972,334Oct 12 08:57 PM
Balo Andrew KEVP, Clinical and RegulatoryOct 05Sale82.555,000412,750111,342Oct 07 05:10 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Sep 23Sale94.0010,300968,196131,009Sep 27 08:15 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerSep 23Sale93.973,182299,00028,643Sep 27 08:14 PM
ROPER JESSSVP, CFOSep 22Sale93.992,470232,15576,686Sep 23 07:52 PM
Balo Andrew KEVP, Clinical and RegulatorySep 21Sale92.875,000464,366116,342Sep 22 06:38 PM
SAYER KEVIN RPresident & CEOSep 14Sale91.797,000642,527306,891Sep 16 05:35 PM
VALDES JORGE ACTOSep 12Sale92.067,071650,9653,499Sep 13 08:30 PM
SKYLER JAY SDirectorSep 12Sale93.0010,000930,0000Sep 14 08:46 PM
KAHN BARBARADirectorSep 12Sale92.905,000464,51224,304Sep 14 08:44 PM
VALDES JORGE ACTOSep 09Option Exercise7.6312,00091,560103,667Sep 13 08:30 PM
SKYLER JAY SDirectorSep 09Sale94.0725,0002,351,78817,246Sep 13 08:51 PM
LISTER JOHNGeneral Manager, EMEASep 09Sale93.653,560333,39287,214Sep 13 08:33 PM
LISTER JOHNGeneral Manager, EMEASep 09Sale93.653,560333,39287,214Sep 13 08:32 PM
VALDES JORGE ACTOSep 09Sale93.6612,0001,123,90991,667Sep 13 08:30 PM
GREGG TERRANCE HExecutive ChairmanSep 08Sale95.595,145491,83065,882Sep 09 08:48 PM
Balo Andrew KEVP, Clinical and RegulatorySep 07Option Exercise3.194,99915,947135,009Sep 09 08:49 PM
FOLETTA MARK GDirectorSep 07Sale94.631,800170,32515,643Sep 09 08:50 PM
GREGG TERRANCE HExecutive ChairmanSep 07Sale95.015,595531,57171,027Sep 09 08:48 PM
Balo Andrew KEVP, Clinical and RegulatorySep 07Sale94.454,999472,156130,010Sep 09 08:49 PM
LORD JONATHAN T MDDirectorSep 01Sale91.5010,000915,00052,820Sep 06 07:34 PM
GREGG TERRANCE HExecutive ChairmanAug 30Sale92.1410,000921,35676,622Sep 01 08:05 PM
Balo Andrew KEVP, Clinical and RegulatoryAug 24Option Exercise3.195,00015,950134,979Aug 26 04:49 PM
Balo Andrew KEVP, Clinical and RegulatoryAug 24Sale91.725,000458,600129,979Aug 26 04:49 PM
GREGG TERRANCE HExecutive ChairmanAug 24Sale92.7210,000927,15186,622Aug 26 06:36 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerAug 23Sale90.893,182289,22431,825Aug 25 04:35 PM